22 results
Oral anticoagulant dosing and bridging for VTE

- Dr. Joseph Shatzel @Clotmaster 

#VTE #DOAC #Bridging #Dosing #Oral
anticoagulant dosing ... DOAC #Bridging #Dosing ... Anticoagulation #Dabigatran #Apixaban ... #Loading #DVT #Pharmacology ... #Hematology
Cutaneous manifestations associated with myelodysplastic syndrome
 • Myeloid hemopathy with the most frequent skin lesions (20%)
most frequent skin ... polymorphism • Satellite ... differential #diagnosis #dermatology ... #oncology #clinical ... #skin
DOAC: Cheat Sheet - Atrial Fibrillation, VTE Prophylaxis, VTE and Renal Dosing

Renal Dosing:
Apixaban (25% renal clearance):
Renal Dosing ... : Apixaban (25% ... Anticoagulation #Hematology ... #Pharmacology # ... Apixaban #Rivaroxaban
NOAC / DOAC Pharmacology and Prescribing Cheat Sheet
Novel (or Direct) Oral Anti-Coagulants
 • Rivaroxaban
 • Apixaban
NOAC / DOAC Pharmacology ... Rivaroxaban • Apixaban ... #NOAC #DOAC #Pharmacology ... #Prescribing #hematology
Switching Between Anticoagulants and DOACs
VKA, Dabigatran, Rivaroxaban, Apixaban, Edoxaban, Betrixaban, DOAC, Parenteral anticoagulant

DOI: 10.1161/JAHA.120.017559

#Anticoagulants #DOACs #anticoagulation
, Rivaroxaban, Apixaban ... anticoagulation #Switching #hematology ... #pharmacology
Anticoagulants Common Reversal Agents
 - Warfarin (Coumadin) → Vitamin K (Phytonadione), 4-factor PCC (Kcentra)
 - Heparin/LMWH
(Praxbind) - Apixaban ... anticoagulation #doac #noac #pharmacology ... #hematology #reversal
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
rivaroxaban, and apixaban ... Rivaroxaban and apixaban ... #Chemotherapy #Oncology ... #Hematology #Interactions ... #Table #Pharmacology
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
management #algorithm #pharmacology ... decisionaid #cardiology #hematology ... #warfarin #dosing
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
for appropriate dosing ... Anticoagulation #Management #Hematology ... #Oncology
The coagulation cascade is shown, separated into different phases with their endogenous and pharmacological inhibitors shown.
During the initiation ... diagnosis #models #hematology ... thrombin #inhibitor #Apixaban